Skip to main content

Metastatic 1st Line Non-Small Cell Lung Cancer HARMONI-3

Status: Open to Enrollment
Email Us To Enroll

Study Details

View study details on clinicaltrials.gov.

Locations

  • Sacramento
  • Palo Alto
  • Roseville
  • Auburn
  • Sunnyvale
  • Fremont

Clinical Trial FAQs

Information for patients and study volunteers, including frequently asked questions.

This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival assessed by investigator. The key secondary endpoints include response and safety.

You're leaving our site

The website you have selected is an external one located on another server. This website may contain links to third party sites. These links are provided for convenience purposes and are not under the control of Sutter Health. Do you wish to continue?